Genzyme third quarter revenue increases to $1.0 billion

Links shared publicly online about this topic.

786
total visits

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme" (alglucosidase alfa) and cost reduction measures.

View full resource at news-medical.net

Tags: Gaucher Disease Medication, Cerezyme, Genzyme, Oncology, News